Aevi Genomic Medicine, Inc. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported Operating loss of $24,285,000 against $27,540,000 a year ago. Net loss was $24,149,000 against $27,555,000 a year ago. Basic and diluted loss per share was $0.40 against $0.74 a year ago. For the nine months, Operating loss was $7,299,000 against $8,569,000 a year ago. Net loss was $7,249,000 against $8,605,000 a year ago. Basic and diluted loss per share was $0.12 against $0.23 a year ago.